ERBB2 and carcinoma: To establish the safety of the mAb104-DX8951, a staggered dose escalation study of 0.5, 1, 2, 4, or 10 mg/kg of the novel mAb104-DX8951 via a single i.v. injection was conducted in mice bearing established HER2 overexpressing (IHC 3+) NCI-N87 carcinoma xenografts.